Ronald Boellaard

Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

I. C. Kok, T. Kwee, J. Gietema, 2018 .

Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma

Ronald Boellaard, Elisabeth Pfaehler, Maqsood Yaqub, 2020, EJNMMI Research.

A Multi-label CNN model for the automatic detection and segmentation of primary brain tumors using 18 F-FET PET imaging

Masoomeh Rahimpour, Ronald Boellaard, Michel Koole, 2022 .

Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake

R. Boellaard, O. Hoekstra, M. Yaqub, 2019, Molecular Imaging and Biology.

Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -

R. Boellaard, O. Hoekstra, J. P. van der Voorn, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer

R. Knol, M. Cysouw, D. Oprea-Lager, 2023, PloS one.

Sensitivity of an AI method for [18F]FDG PET/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols

J. Zijlstra, S. Golla, Bart M. de Vries, 2023, EJNMMI Research.

Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma

J. Zijlstra, H. Schöder, C. Moskowitz, 2023, Blood advances.

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

W. Oyen, R. Boellaard, G. V. van Dongen, 2019, European Journal of Nuclear Medicine and Molecular Imaging.

Integration of FDG- PET/CT into external beam radiation therapy planning

U. Pietrzyk, W. V. Elmpt, D. Ruysscher, 2012, Nuklearmedizin.

Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study.

R. Boellaard, P. Bossuyt, O. Hoekstra, 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET

J. Zijlstra, C. W. Menke-van der Houven van Oordt, Y. Jauw, 2024, EJNMMI research.

The development process of ‘fit-for-purpose’ imaging biomarkers to characterize the tumor microenvironment

J. Waterton, J. J. Eertink, Ronald Boellaard, 2024, Frontiers in medicine.

89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied?

R. Boellaard, G. V. van Dongen, A. Windhorst, 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....